

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Prestige Consumer Healthcare
Deal Size : $230.0 million
Deal Type : Divestment
Akorn Announces Agreement to Sell its Consumer Health Business to Prestige Consumer Healthcare
Details : The Consumer Health business primarily consists of the following over-the-counter brands: TheraTears , Diabetic Tussin , MagOx , Multi-betic , and Zostrix.
Product Name : TheraTears
Product Type : Carbohydrate
Upfront Cash : $230.0 million
May 27, 2021
Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Prestige Consumer Healthcare
Deal Size : $230.0 million
Deal Type : Divestment

Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Akorn Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops
Details : TheraTears (Sodium Carboxymethylcellulose) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Product Name : TheraTears
Product Type : Carbohydrate
Upfront Cash : Inapplicable
May 02, 2016
Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Akorn Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms
Details : Sodium Carboxymethylcellulose is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
January 07, 2014
Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
